secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001372514-23-000097
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals closes $6.3M underwritten public offering, including full over-allotment
--------------------------------------------------------------------------------

- Gross proceeds of $6.3M from offering of common stock, Series F convertible preferred, and Class C/D warrants.
- Net proceeds to Kiora approximately $5.6M after underwriting discounts and offering expenses.
- Underwriter's over-allotment option fully exercised, adding 750,000 common shares and warrants.
- Series F preferred convertible into common; holder limited to 4.99% beneficial ownership (can increase to 9.99%).
- Class C warrants expire in 5 years, Class D in 1 year; both have initial exercise price of $1.10 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/0001372514-23-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/kprx-20230602.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer